| Literature DB >> 31838081 |
Jangho Lee1, Ju-Yong Hyon2, Jin Young Min3, Yang Hoon Huh4, Hyo Jung Kim4, Hayoung Lee5, Sung Ho Yun4, Chi-Won Choi6, Su Jeong Ha7, Joon Park8, Young-Ho Chung3, Hye Gwang Jeong9, Sang Keun Ha1, Sung Keun Jung10, YoonSook Kim11, Eun Hee Han12.
Abstract
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease in the world. Advanced glycation end products (AGEs) are thought to be involved in the pathogenesis of DN via multifactorial mechanisms including the generation of oxidative stress and overproduction of various growth factors and cytokines. AGEs are heterogeneous cross-linked sugar-derived proteins, and Nε-(carboxymethyl)-lysine (CML)-conjugated BSA is a major component of AGEs. However, the proteins involved in DN induction by CML have never been reported. Herein, we investigated specific protein regulators of AGE-mediated DN via proteomic analysis of streptozotocin (STZ)-induced diabetic mice kidneys. We identified 937, 976, and 870 proteins in control, STZ, and STZ + CML-BSA samples, respectively. Bioinformatics analysis identified several CML-mediated proteins potentially involved in kidney damage, activation of fatty acid oxidation (FAO), and mitochondrial dysfunction. Furthermore, we identified the CML-specific differential protein carnitine palmitoyltransferase 2 (CPT2), related to FAO. To confirm the effect of CPT2 and the CML-mediated mechanism, human renal tubular HK-2 cells were treated with CML-BSA and cpt2 siRNA, and examined for FAO-mediated fibrosis and mitochondrial dysfunction. CML-BSA and CPT2 knockdown induced fibrosis-related gene expression and damage to mitochondrial membrane potential. Moreover, CPT2 overexpression recovered CML-induced fibrosis-related gene expression. Based on these results, a decrease in CML-induced CPT2 expression causes mitochondrial FAO damage, leading to renal fibrosis and DN.Entities:
Keywords: Advanced glycation end products; Carnitine palmitoyltransferase 2; Diabetic nephropathy (DN); End-stage renal disease; Mitochondrial dysfunction; N(ε)-(carboxymethyl)-lysine
Mesh:
Substances:
Year: 2019 PMID: 31838081 DOI: 10.1016/j.phrs.2019.104600
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658